Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shubaile
- Development stage
- Phase 1
- Lead developer
- Beijing Shuobai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Shubaile (101BHG-D01) is a selective M3 muscarinic receptor antagonist developed as an intranasal spray for the treatment of chronic rhinitis. Developed by Beijing Shuobai Pharmaceutical Technology, the drug is designed to alleviate symptoms such as rhinorrhea and nasal congestion by blocking acetylcholine-mediated glandular secretion and vasodilation in the nasal passages. By specifically targeting the M3 receptor subtype, Shubaile aims to provide a more targeted therapeutic effect with a potentially improved safety profile compared to non-selective anticholinergic agents. It has been evaluated in Phase Ib/IIa clinical trials in China to assess its safety, tolerability, and preliminary efficacy in adult patients with chronic rhinitis.
- Brand names
- Shubaile
02
Targets
CHRM3 (M3)
Beyond the preview
Go deeper on Shubaile.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shubaile.